Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

orporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; and other risks and uncertainties which may not be described herein. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F for and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission.

Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or developments.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Mass. (PRWEB) , ... July 06, 2015 , ... ... of simpler and cheaper molecular diagnostic tests are key drivers of the global ... growth of personalized medicine and the introduction of new companion diagnostic tests will ...
(Date:7/6/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... Novella Clinical (Novella), to conduct the phase 3 ... glioblastoma. Novella is a full-service, global clinical research organization ... oncology companies. The ICT-107 phase 3 trial will include ... Europe and Canada , ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander ... and professional service industries alike-- typically known for its consummate professionalism-- embarks each ... good cause and break from their day jobs. , "Our motto has always ...
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces that ... Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ) ... in United States District Court, Central District of ... on behalf of a class consisting of all persons ... 2014 and May 13, 2015 inclusive (the "Class Period").  ...
Breaking Biology Technology:Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4
... 75 percent, SANTA CRUZ, Calif., Aug. 26 ... communities of its member,schools in finding the "perfect match," ... fee reduction., An online job board and careers ... ) has,dropped its fee to $50 per academic postdoc ...
... In situ live cell manipulation on LEAP(TM) to empower ... ... Aug. 26 Cyntellect, a privately-held,biotechnology company, and the ... entered into a joint collaboration to,develop new applications on ...
... cells are not pampered pushovers. O,Reilly et al. report ... molding their environment to control their division and differentiation., ... cradle them in a structure called the niche. The ... their behavior, determining whether they reproduce and specialize. The ...
Cached Biology Technology:Online Career Site Assists Academia in Its Reach 2Cyntellect to Collaborate With the Burnham Institute for Medical Research 2Cyntellect to Collaborate With the Burnham Institute for Medical Research 3
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
(Date:6/10/2015)... , June 10, 2015 ... "3D Sensor Market by Technology (Ultrasound, TOF, Structured ... (consumer Electronics, Entertainment, Automotive) and by Geography - ... by MarketsandMarkets, the market is expected to reach ... of 25.51% between 2015 and 2020. ...
(Date:6/9/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) ... Recognition & Touchless Sensing Market by Technology (Touch-based ... Product (Biometric & Sanitary Equipment) & by Geography ... their offering. The total gesture recognition ... $ 23.55 Billion by 2020 at a high ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 23D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... A mother,s iron deficiency early in pregnancy may have ... the child, even if the lack of iron is not ... Rochester Medical Center study published in the scientific journal ... might not notice or treat mild or moderate iron deficiency, ...
... 2011) - An animal,s behavior is probably its ... Its behavior involves processes internal to the animalgenetics, neurobiology, ... social surroundings. According to the book,s authors, "Animal behavior ... sparked when neurons fire in response to stimuli in ...
... In recent years, researchers have worked to develop more ... in Afghanistan or Iraq with missing arms or legs. ... entering the body through the space where the device ... area) where the bacteria would enter the body, and ...
Cached Biology News:Pre-conception and early pregnancy iron deficiency harms brain 2Pre-conception and early pregnancy iron deficiency harms brain 3New book on animal behavior provides integrated view 2Nanomodified surfaces seal leg implants against infection 2
... all the reagents required for a fast ... activity in cell and tissue extracts and ... has been tested on samples prepared from ... spleen, and heart muscle from several species, ...
... CHEMICON's Skeletal Myogenesis Kit provides the ... myoblasts into mature skeletal myotubes. By ... is a valuable tool in studies ... in developing strategies for muscle cell ...
... is an anchorage-independent growth assay in soft ... assay for detecting malignant transformation of cells. ... carcinogens or carcinogen inhibitors) are cultured with ... 21-28 days. Following this incubation period, ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
Biology Products: